Cordance Medical

What Cordance Medical does

Cordance Medical is a privately held medical device company founded in 2018 and headquartered at 2483 Old Middlefield Way, Suite 120, Mountain View, California. The company is developing the NeuroAccess platform, a portable, non-invasive focused ultrasound device that temporarily and reversibly opens the blood-brain barrier (BBB) by combining low-frequency ultrasound with microbubbles. Two named applications sit on this hardware layer: SonoBiopsy, which elevates circulating tumor DNA and other biomarkers into the bloodstream to enable liquid-biopsy diagnostics, and SonoScript, which enhances brain biodistribution of therapeutic agents for targeted drug delivery. The platform is designed for 30-minute outpatient procedures without head fixation or live imaging, distinguishing it from MRI-guided focused ultrasound systems.

Cordance targets neuro-oncology (gliomas, glioblastoma multiforme, and brain metastases), Alzheimer's disease, Parkinson's disease, and broader neurological disorders where the BBB blocks approximately 98% of molecules from reaching the brain. The company's go-to-market is an enterprise field sales motion directed at academic medical centers and community outpatient clinics, with planned first-in-human trials at UCSF, Washington University, Stanford, Duke, and Barrow Neurologic Institute. Strategic partners include EXACT Therapeutics (combined ACT therapy), Microvascular Therapeutics (MVT-100 microbubbles), Abyssinia Biosciences (Alzheimer's antibodies), Stanford Medicine (precision neuropsychiatry via ultrasonic drug uncaging), and Washington University (SonoBiopsy IP licensing). The company has received FDA Breakthrough Device Designation (October 2023) and FDA TAP Program acceptance, and holds granted patents across the US, EU, Japan, and Australia.

Cordance is pre-revenue and pre-commercial, with revenue expected to be generated through hardware sales of the NeuroAccess device to hospitals and outpatient clinics once regulatory clearance is secured. The company has raised approximately $8 million in an oversubscribed November 2025 seed round led by Sonder Capital, supplemented by roughly $1.25 million in non-dilutive grants from the NSF (Phase I $250K in 2019 and Phase II ~$1M in 2021) and NIH/NCI (SBIR Phase I grant R43CA295307 in September 2024). Total disclosed funding is approximately $9.25 million against a stated headcount of 1-10 employees.

Name

Cordance Medical

Legal name

Cordance Medical

Website

https://cordancemedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Cordance Medical is a private medical device company developing NeuroAccess, a non-invasive focused ultrasound platform that temporarily opens the blood-brain barrier to enable precision drug delivery (SonoScript) and liquid biopsy diagnostics (SonoBiopsy) for brain cancer, Alzheimer's, Parkinson's, and other neurological diseases.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Focused ultrasound devices
• Blood-brain barrier opening
• Non-invasive neurology
• Brain drug delivery
• Liquid biopsy platform

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Pre-commercial medical device company planning to generate revenue through sale of its NeuroAccess focused ultrasound platform to hospitals, neuro-oncology centers, and outpatient clinics. The company is currently in preclinical/clinical trial stage with first-in-human trials planned.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Cordance Medical develops the NeuroAccess platform, a portable, non-invasive focused ultrasound medical device that temporarily opens the blood-brain barrier (BBB) by combining low-frequency ultrasound with microbubbles. The system enables two primary applications: SonoBiopsy for liquid biopsy diagnostics and SonoScript for precision drug delivery, targeting brain cancers, Alzheimer's, Parkinson's, and other neurological disorders.

Product overview

Cordance Medical offers the NeuroAccess Platform as its core unified medical device system, with two key applications: SonoBiopsy for liquid biopsy diagnostics and SonoScript for precision drug delivery. The platform uses focused ultrasound combined with microbubbles to temporarily and reversibly open the blood-brain barrier in a 30-minute or less outpatient procedure, enabling both diagnostic and therapeutic applications for brain cancers, Alzheimer's, Parkinson's, and other neurological conditions.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroAccess: Non-invasive focused ultrasound platform designed to temporarily and safely open the blood-brain barrier for liquid biopsy and drug delivery applications in brain disease treatment.
• SonoBiopsy
• SonoScript

Products and services

• NeuroAccess Platform A portable, non-invasive focused ultrasound medical device that temporarily opens the blood-brain barrier by combining low-frequency ultrasound with microbubbles. Designed for outpatient clinic use without requiring MRI, patient head fixation, or live imaging during treatment. Intended for hospitals, neuro-oncology centers, and outpatient clinics treating patients with brain cancers and neurological diseases.
• SonoBiopsy An application of the NeuroAccess platform that enables real-time genomic characterization of brain disease through liquid biopsy. It temporarily opens the BBB to allow circulating tumor DNA and biomarkers to enter the bloodstream for blood-based testing. Intended for adult patients with known or suspected brain tumors.
• SonoScript A precision-guided drug delivery application using focused ultrasound to enhance brain biodistribution of therapeutic agents and antibodies to diseased brain regions. Targeted at enabling chemotherapy, immunotherapy, and antibody therapy delivery across the blood-brain barrier.

Quantifiable outcome

• More than doubling (127-145%) of radiopharmaceutical uptake in brain tumors in mice models when combining Cordance's technology with EXACT Therapeutics' ACT technology

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered secondary and core.

• Abyssinia BiosciencessecondaryStrategic or Co-development Partner · 23 January 2025Collaboration to explore focused ultrasound in diagnostic and therapeutic applications for Alzheimer's disease. Using SonoBiopsy technology for early identification of toxic amyloid abnormalities and SonoScript technology to investigate BBB opening for enhanced brain biodistribution of Abyssinia's therapeutic antibodies targeting amyloid oligomers.
• Microvascular Therapeutics (MVT)coreStrategic or Co-development Partner · 16 September 2024Strategic partnership for MVT to supply MVT-100 microbubble product for research with Cordance's NeuroAccess technology to open the blood-brain barrier. MVT is developing FDA-approved microbubbles specifically for BBB opening application. No microbubbles currently FDA-approved for this specific use.
• Stanford Medicine (Airan and Williams Labs)coreStrategic or Co-development Partner · 6 December 2023Agreement with Dr. Raag Airan and Dr. Nolan Williams at Stanford Medicine to explore precision neuropsychiatry using ultrasonic drug uncaging technology. NeuroAccess will be used to 'uncage' drug-loaded nanoparticles within targeted brain areas, enabling focal non-invasive drug delivery with Dr. Airan's nanoparticle technology. First trial to use nanoparticle-bound ketamine for chronic pain.
• BLOODPAC ConsortiumsecondaryStrategic or Co-development Partner · 20 October 2023Membership in BLOODPAC (Blood Profiling Atlas in Cancer) Consortium, a non-profit organization accelerating development and validation of liquid biopsy tests. Cordance contributes learnings and knowledge to create standards for SonoBiopsy procedures and facilitate collaborative research and data sharing.
• Washington University in St. LouiscoreTechnology or Integration · 28 September 2023Strategic licensing agreement granting Cordance rights to patent and patent-pending technologies related to SonoBiopsy technology developed by Dr. Eric Leuthardt and Dr. Hong Chen. IP covers use of focused ultrasound to open BBB for analyzing molecular information through liquid biopsy.
• EXACT TherapeuticscoreStrategic or Co-development Partner · 6 September 2023Strategic partnership combining Cordance Medical's NeuroAccess platform with EXACT Therapeutics' Acoustic Cluster Therapy (ACT) technology for enhanced drug delivery across the blood-brain barrier. ACT uses proprietary microbubble-microdroplet clusters (PS101) activated by ultrasound for targeted drug enhancement. Collaboration aims to deliver more effective drug therapy across BBB for brain tumors and neurodegenerative disorders.
• Focused Ultrasound FoundationsecondaryOthersPartner organization in the focused ultrasound ecosystem providing support and advocacy for the technology area.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CarThera: French clinical-stage company developing the SonoCloud implantable ultrasound device for transient BBB opening, with published clinical data in recurrent glioblastoma — the most direct competitor to Cordance's NeuroAccess in the non-invasive / minimally-invasive BBB opening space.
• NaviFUS: Taiwan-based clinical-stage company developing transcranial focused-ultrasound systems for BBB opening in brain tumor and other CNS indications — directly comparable technology targeting overlapping indications.

Broad incumbents

• InSightec: Established focused-ultrasound incumbent with the Exablate Neuro platform FDA-cleared for essential tremor, tremor-dominant Parkinson's, and approved for additional neurosurgical indications — a deep-pocketed incumbent that could expand into BBB-opening use cases and competes for the same hospital and KOL relationships.
• Profound Medical: Commercial-stage therapeutic ultrasound company (TULSA-PRO for prostate, Sonalleve for uterine fibroids) with an installed base and regulatory experience relevant to Cordance's commercial planning.
• EDAP TMS: Commercial-stage high-intensity focused ultrasound company (Ablatherm, Focal One) with regulatory and manufacturing know-how in HIFU device commercialization that is structurally analogous to Cordance's go-to-market.
• Theraclion: European therapeutic ultrasound company (Echopulse) treating thyroid, breast and varicose vein indications — provides an analog for commercializing non-invasive focused-ultrasound devices into outpatient specialty practices.

Emerging players

• Delsona Therapeutics: Emerging BBB-drug-delivery company developing biologic payloads enabled by BBB-opening technologies — comparable end-customer (neuro-oncology pharma) and overlapping scientific concept.
• Acoustic Therapeutics: Early-stage company developing focused-ultrasound approaches for non-invasive BBB modulation — partial-overlap emerging player operating in the same scientific niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CordanceM
• LinkedInlinkedin.com/company/cordance-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cordance Medical